M
Michael C. Perry
Researcher at University of Missouri
Publications - 105
Citations - 12591
Michael C. Perry is an academic researcher from University of Missouri. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 39, co-authored 105 publications receiving 12010 citations. Previous affiliations of Michael C. Perry include University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan B. Sandler,Robert Gray,Michael C. Perry,Julie R. Brahmer,Joan H. Schiller,Afshin Dowlati,Rogerio Lilenbaum,David H. Johnson +7 more
TL;DR: The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths.
Journal ArticleDOI
A meta-analysis of thoracic radiotherapy for small-cell lung cancer.
Jean Pierre Pignon,Rodrigo Arriagada,Daniel C. Ihde,David H. Johnson,Michael C. Perry,Robert L. Souhami,Ola Brodin,Rudolf A. Joss,Merrill S. Kies,Bernard Lebeau,Taisuke Onoshi,Kell Østerlind,Martin H.N. Tattersall,Henry Wagner +13 more
TL;DR: Thoracic radiotherapy moderately improves survival in patients with limited small-cell lung cancer who are treated with combination chemotherapy, and identification of the optimal combination of chemotherapy and radiotherapy will require further trials.
Journal ArticleDOI
Hepatotoxicity of Chemotherapy
Paul D. King,Michael C. Perry +1 more
TL;DR: A comprehensive understanding of hepatotoxic manifestations for the most common chemotherapeutic agents is essential because dose modifications often rely on empirical clinical judgement.
Journal ArticleDOI
A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer
Steven M. Keller,Sudeshna Adak,Henry N. Wagner,Arnold Herskovic,Ritsuko Komaki,Burke J. Brooks,Michael C. Perry,Robert B. Livingston,David H. Johnson +8 more
TL;DR: As compared with radiotherapy alone, adjuvant radiotherapy and chemotherapy with cisplatin and etoposide does not decrease the risk of intrathoracic recurrence or prolong survival in patients with completely resected stage II or IIIa non-small-cell lung cancer.
Journal ArticleDOI
Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599
Alan Sandler,Robert Gray,J. Brahmer,A. Dowlati,Joan H. Schiller,Michael C. Perry,David H. Johnson +6 more
TL;DR: This randomized phase II trial of PC +/- bevacizumab (A) suggested improved activity for the combination of PCA when compared to PC alone, and multivariate analysis suggested squamous cell histology to be a significant risk factor.